Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer.
Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer (UC).
In UC alterations in FGFR3, PIK3CA, and CDKN2A have become actionable targets for therapy. Clinical research has begun to explore how genomic alterations interact with tumors to shape understanding that can aid in treatment.
0:08 | We've been learning a lot over the past few years about the genomic underpinnings of bladder cancer. And the role of genomic testing is expanding almost every year as we learn more about the role of genomic alterations in the pathogenesis and the natural history, and response to treatment in patients with bladder cancer.
0:37 | So, for example, this year, we are learning a lot more about the germline the role of the germline variants in urothelial. cancer and germline variants are these alterations that we're all born with, that are inherited. And we're this year we published a manuscript in Nature Communications that looked at the role of germline alterations or germline variants in bladder cancer patients, and we identified several common germline variants in these patients, which is consistent with other findings that are emerging from other groups. And we're now trying to understand how these germline alterations interact with the cancer somatic alterations to shape the course of bladder cancer.